Precision Biologics Successfully Completes Safety Phase and Begins Enrollment in Phase 2 Trial Combi
BETHESDA, Md.--(BUSINESS WIRE)--Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, announced today the successful completion of the safety phase and the enrollment of new patients into the expansion of the Phase 2 Clinical Trial Combining Precision Biologics NEO-20...
Source: pharmiweb.com
